Peloton Therapeutics, Inc., a Dallas-based early-stage cancer drug discovery and development company, completed an $18m Series A financing.
The round was led by The Column Group, with participation from Remeditex Ventures and Peter O’Donnell, Jr.
Working in close collaboration with scientists at UT Southwestern, Peloton is advancing a promising discovery and development pipeline, comprised of several small molecule-based programs, each with a distinct target and mechanism of action.
The company was founded by scientist Steven L. McKnight, Ph.D., and its Board of Directors includes:
– Nobel Laureate Michael S. Brown, M.D., Regental Professor of the University of Texas System and Director of UT Southwestern’s Erik Jonsson Center for Research in Molecular Genetics and Human Disease; – John W. Creecy, CEO, Remeditex Ventures;
– David V. Goeddel, Ph.D., Managing Partner, The Column Group;
– Tim Kutzkey, Ph.D., Partner, The Column Group; and
– Brett A. Ringle, President, Remeditex Ventures.
John A. Josey, Ph.D., former Vice President of Discovery Chemistry at Array BioPharma, Inc., will join Peloton as President and Chief Scientific Officer.
This Series A funding supplement a recently awarded $11m grant from the Cancer Prevention and Research Institute of Texas (CPRIT).